Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."